Compare BioNano Genomics Inc (BNGO) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Honeywell International Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Honeywell International Inc trades at $234.2 (market cap $72.93B). The key difference: Honeywell International Inc is far larger — about 5338.9× BioNano Genomics Inc's market cap, and Honeywell International Inc pays a 1.22% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | HON | |
|---|---|---|
Market Cap | $13.66M | $72.93B |
Sector | Health | Industrials |
52-Week High | $4.92 | $248.79 |
52-Week Low | $1.06 | $188.14 |
Enterprise Value | $16.26M | $97.73B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Honeywell International Inc. (HON) trades at $232.35, down 4.36% amid disappointing growth guidance from a recent investor event. The stock exhibits bearish technical signals with support near $225, while fundamentals remain solid with a low P/E of 8.85 and strong profitability margins. Recent corporate actions include dividend payments and business divestitures, positioning the company as a focused automation play.
The outlook is mixed: attractive valuation and consistent earnings beats support upside toward the $320.54 consensus target, but near-term sentiment is pressured by growth concerns and technical weakness. Key risks include execution of the portfolio transformation and macroeconomic headwinds affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
